Active Filter(s):
Details:
The approval allows Kato to study the efficacy of Resolv ER, first-in-class patented formulation therapeutic drug is intended to separate the vitreous from the retina on VMA which may lead to retinal tears, retinal detachment, and macular holes.
Lead Product(s): Liposome-loaded urea compound
Therapeutic Area: Ophthalmology Product Name: Resolv ER
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2022